This article was first published by The Times of Israel and is re-posted with permission.
A prospective oral coronavirus vaccine is set to start clinical trials in Israel, and the developer believes it could help get vaccines to countries that are struggling to inoculate because of limited infrastructure.
Oramed Pharmaceuticals has created a single-dose oral version of a prospective vaccine being developed by India-based Premas Biotech, and in March announced that it had successfully generated antibodies in pigs.
It hopes that the Israeli-developed pill will be suitable as a simple initial vaccination, as it won’t need to be stored at low temperatures and eliminates the need to have professionals administering injections.
This could be a “game-changer” in countries like India, where only 5 percent of the population has been vaccinated, said Nadav Kidron, CEO of Oramed.
To read the full article, click here.